• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

A Reprieve In These Turbulent Times

Biotech Letter

Following a punishing 2022, it’s reasonable to expect that the situation won’t get any better, especially with a recession hanging over our heads this 2023. Hence, industries widely known to be “resilient,” “stable,” and “durable” will sustain their momentum and continue to gain more investors. Meanwhile, sectors typically associated with “buzzy” updates will struggle to keep their businesses afloat.

That means the best businesses to put your money in are those where people have no other recourse but to spend regardless of the economic situation. With this in mind, investors are projected to load up on healthcare stocks to help them weather the incoming financial storm.

Actually, this has been the trend since the pandemic started, with the Health Care Select Sector SPDR ETF (XLV) only falling by 4.2% in 2022. It’s still good news, especially in light of significant tailwinds, like wars, inflation rates, and political turmoil. Looking at the performance of this sector, it’s evident that people will still seek medical care no matter what. That makes the healthcare sector the ideal combo of a reasonable valuation and defense.

Among the names in this segment, finding a company that performed better than Vertex Pharmaceuticals (VRTX) would be difficult. This business has swum against the tide throughout 2022, with shares climbing amid the struggles of the S&P 500. While Vertex already presented solid fundamentals this year, it could perform even better in 2023.

Vertex’s shares have risen by 32% year to date. In contrast, the S&P 500 has shown a 19% decline. What makes Vertex different from its competitors? Here is the short answer. The company is equipped with the tools to continue delivering impressive financial results in both the short and long terms.

The next couple of years will see Vertex continue to lean on its high-performing lineup of treatments that target cystic fibrosis (CF). This rare genetic condition results in digestive issues and affects the internal organs of patients.

Vertex has a virtual monopoly of this highly lucrative market, being the sole game in town targeting not only CF but the underlying conditions of this rare disease.

Actually, Vertex has been aggressive in expanding its CF franchise. Before 2022 wrapped up, the company submitted its Investigational New Drug application for another CF treatment called VX-522. This is an mRNA-based therapy, which was already cleared by the US Food and Drug Administration.

The CF market has massive potential, which Vertex has yet to explore fully. By 2025, the CF market is estimated to hit a whopping $13.9 billion. Considering that Vertex is the only drugmaker making an impact on this condition, this could translate to an even bigger revenue stream for the company.

Vertex’s lineup of CF treatments has enabled the company to start creating and developing new programs that hold the potential to become blockbusters. Thus far, the company has developed a pipeline of candidates for gene-editing and acute pain treatments.

To date, Vertex and its co-developer, CRISPR Therapeutics (CRSP), are awaiting regulatory approval for their one-time gene-editing therapy called Exa-cel. This treatment has the potential to cure two rare genetic blood diseases, namely, sickle cell disease and transfusion-dependent beta-thalassemia. Apart from being able to possibly treat these conditions, the capability of Exa-cel to eliminate the necessity for transfusions makes it incredibly impressive.

Another potential top-selling treatment for Vertex is VX-548, which targets neuropathic and acute pain. This is a non-opioid alternative that the company hopes to offer in an effort to curb the debilitating opioid addiction in the US. VX-548 is slated to undergo Phase 3 trials in the first half of 2023.

Overall, Vertex is an excellent buy for investors looking for a safe and solid stock in the healthcare industry. It has proven itself to be an extremely profitable company over the past decade, and its pipeline of potential treatments queued for clinical trials are indicative of its ability to grow beyond its CF program. Given Vertex’s success over the years, the business potential, and the current price, this company can quickly become a crowd favorite in 2023.

 

vertex company

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-01-03 16:00:212023-01-10 13:54:42A Reprieve In These Turbulent Times
You might also like
Five Biotech Stocks to Buy at the Bottom
The Future of Gene-Editing Therapy
October 4, 2022
February 15, 2022
January 23 Biweekly Strategy Webinar Q&A
From Limping To Leaping

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Link to: Trade Alert - (GOLD) January 3, 2023 - BUY Link to: Trade Alert - (GOLD) January 3, 2023 - BUY Trade Alert - (GOLD) January 3, 2023 - BUY Link to: January 3, 2023 Link to: January 3, 2023 January 3, 2023
Scroll to top